Abstract:Smads, the intracellular effectors of transforming growth factor-β (TGF-β) family members, are somatically mutated at high frequency in particular types of human cancers. Certain of these mutations affect the Smad amino-terminal domain, which, in the case of Smad3 and Smad4, binds DNA. We investigated the functional consequences of four missense mutations in the Smad4 amino-terminal domain found in human tumors. The mutant proteins were found to have impaired abilities to bind DNA although they were fully capable of forming complexes with Smad3. All four Smad4 mutants showed decreased protein stability compared to wild-type Smad4. Two of the Smad4 mutants (G65V and P130S) were translocated to the nucleus and were capable of transactivating a Smad-dependent promoter in a ligand-dependent manner. In contrast, the L43S and R100T mutants were not translocated efficiently to the nucleus and consequently resulted in severely defective transcriptional responses to TGF-β. Moreover, we demonstrate here the critical importance of two basic residues in the β-hairpin loop of Smad3 or Smad4 for DNA binding, consistent with predictions from the Smad3 crystal structure. In addition, our results reveal that in the TGF-β-induced heteromeric signaling complex, loss of DNA binding of Smad4 can be compensated by Smad3, however, both Smad3 and Smad4 are needed for efficient DNA binding and signaling. In conclusion, mutations in the amino-terminal domain of Smad4, that are found in cancer, show loss of multiple functional properties which may contribute to tumorigenesis.

Regulation of Large-Scale Chromatin Unfolding by Smad4

[Involvement of LMO4 in Tumorigenesis Associated Epithelial-Mesenchymal Transition].

Posttranslational Regulation of Smads

Activation of Transforming Growth Factor-β Signaling by SUMO-1 Modification of Tumor Suppressor Smad4/DPC4*

Functional consequences of tumorigenic missense mutations in the amino-terminal domain of Smad4

Sumo-1/Ubc9 Promotes Nuclear Accumulation And Metabolic Stability Of Tumor Suppressor Smad4

The Tumor Suppressor Smad4/Dpc4 and Transcriptional Adaptor Cbp/P300 Are Coactivators for Smad3 in Tgf-Beta-Induced Transcriptional Activation

Consequences Of Mutations And Abnormal Expression Of Smad4 In Tumors And T Cells

Smad4 Sequestered in SFPQ Condensates Prevents TGF-β Tumor-Suppressive Signaling.

Ligand-dependent ubiquitination of Smad3 is regulated by casein kinase 1 gamma 2, an inhibitor of TGF-β signaling

Ligand-dependent ubiquitination of Smad3 is regulated by casein kinase 1 gamma 2, an inhibitor of TGF-beta signaling.

The role of TGF-β/SMAD4 signaling in cancer

Ubiquitination and Proteolysis of Cancer-Derived Smad4 Mutants by Scfskp2

Axin and GSK3- Control Smad3 Protein Stability and Modulate TGF- Signaling.

Post‐translational Regulation of TGF‐β Receptor and Smad Signaling

SMAD4 promotes TGF-β-independent NK cell homeostasis and maturation and antitumor immunity.

Advances in Research on Smad4

Human Smad3 and Smad4 Are Sequence-Specific Transcription Activators

TGF-β-induced nuclear localization of Smad2 and Smad3 in Smad4 null cancer cell lines

Formation of a Stable Heterodimer Between Smad2 and Smad4.